Participated · Series B · Aug 2024

NeuroTherapia, led by President and CEO Tony Giordano and based in Cleveland, OH, is a clinical-stage biotech developing oral, small-molecule drugs to address neuro-inflammatory CNS conditions including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Its lead program, NTRX-07, is an orally available cannabinoid receptor agonist intended to inhibit microglia-mediated inflammation without affecting clearance of toxic beta amyloid. The company says its therapeutics aim to inhibit proteins expressed by microglia that drive CNS inflammation while preserving amyloid clearance. NeuroTherapia raised $12.3M in a Series B financing and intends to use the proceeds for continued clinical development of NTRX-07. The company plans a second close in six months to raise additional funds to enable development of a recently discovered second-generation molecule for a separate indication driven by neuroinflammation. No operating metrics (revenue/users) were disclosed in the article. NeuroTherapia is an early-stage clinical pharmaceutical company developing NTRX-07, a first-in-class drug candidate for Alzheimer’s disease. The company announced it has received a grant from the Alzheimer’s Association Part the Cloud program to support development of NTRX-07. NTRX-07 is being developed as a treatment for Alzheimer’s disease. The grant provides funding to advance the program through development. As an early-stage clinical firm, NeuroTherapia's near-term plans center on progressing NTRX-07. The company issued the announcement in a press release from NeuroTherapia, Inc. NeuroTherapia is a Cleveland, OH-based clinical-stage company developing NTRX-07, an orally available cannabinoid receptor agonist aimed at treating neuroinflammation implicated in neurodegenerative diseases. The company is completing its first-in-human clinical trial of NTRX-07, with part of the trial funded by an Alzheimer’s Association grant. It closed an $8.8M Series A to finish the first-in-human work and to undertake additional preclinical studies. The planned preclinical studies are intended to support subsequent clinical trials by demonstrating safety following longer-term administration and showing biological activity. Separately, NeuroTherapia received a $150,000 Technology Validation and Start-up Fund grant from Ohio Third Frontier to complete biodistribution research after radiolabeling the molecule. The company also strengthened its board with the addition of Karoly Nikolich, Ph.D., joining existing board members including the chairman Mr. Reher, President and CEO Tony Giordano, Ph.D., and Akhil Saklecha, M.D., from Cleveland Clinic.